Clinical trial · Observational
Retroprospective Real Life Observatory of Eribulin
Activity and Toxicity Profile of Eribulin Mesylate in Pretreated Metastatic Breast Cancer: an Observational Multicentric Retroprospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this observatory is to evaluate the effecacy of Eribulin in patients with metastatic breast cancer on a recent prescription period. Part of the data collection will be retrospective and the other part will be prospective for patients started treatment by Eribulin between November 2014 and September 2015. It will allow a better assessment on the safety profile of this drug.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Eribulin (ReProLine) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Reproline
- description
- this is an observational trial ; there is no intervention
- interventionNames
- Other: Eribulin (ReProLine)
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 1 year
- description
- Overall survival is defined as the time between the first administration of Eribulin and death from any cause.
Secondary outcomes (4)
- measure
- Overall Survival by subgroup
- timeFrame
- 1 year
- description
- Overall survival is defined as the time between the first administration of Eribulin and death from any cause in the following subgroups: * According to the administration line of Eribulin: administration in third line or more versus administration in first or second line or for locally advanced cancer, * in HER2 + population * in triple negative population * in the elderly (\> 70 years) * in the overweight population (BMI\> 30)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years 2. Patient with breast cancer, histologically proven, metastatic or locally advanced 3. Patient treated by Eribulin between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part). 4. Patient with at least an assessment of the response to Eribulin Exclusion Criteria: 1. Presence of other neoplasia 2. Man
References
Publications (0)
Data not yet available